Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World
Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted,
Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and
Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and
Brings internationally recognized expertise in immunology, cytokine biology, host-microbe interactions and public health
Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing
Martin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic advisory experience
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by
Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent
Dr. Stephen M.
Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing
Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic
Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as
Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7,
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9%
Study demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression
First in a planned series of peer-reviewed publications exploring the
Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will
Dr. Hahn Brings Unparalleled Clinical and Regulatory Expertise to Support Advancement of GX-03 for Moderate-to-Severe Atopic Dermatitis and Pipeline Indications
Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage
